



GENTING

BERHAD

Registration No. 196801000315 (7916-A)

PRESS RELEASE

For Immediate Release

**GENTING BERHAD'S ASSOCIATE, TAURX PHARMACEUTICALS LTD., ANNOUNCED MOVE
TOWARD REGULATORY SUBMISSION BASED ON INITIAL DATA FROM
TAURX'S LUCIDITY TRIAL**

KUALA LUMPUR, 1 JUNE 2022 - Genting Berhad today announced that its associate, TauRx Pharmaceuticals Ltd. ("TauRx"), a leader in tau-based research in Alzheimer's, had on 31 May 2022 unveiled initial data from the completion of the randomised portion of their pivotal Phase 3 clinical trial, LUCIDITY (NCT03446001). As at 31 March 2022, Genting Berhad holds about 20.3% of the equity in TauRx. For a copy of TauRx's official announcement, please visit:

<https://ts-assets.ams3.cdn.digitaloceanspaces.com/mg/tx/pdfs/Lucidity-Data-Announcement.31May2022.for-website.pdf>

TauRx Announcement Highlights:

- **LUCIDITY data suggest that participants receiving hydromethylthionine mesylate ("HMTM") decline at a rate substantially less than is typical in Alzheimer's based on published research**
- **Safety profile is favourable and consistent with previous HMTM studies**
- **TauRx will now pursue regulatory submission and coverage for HMTM**

TauRx's lead investigative oral drug, HMTM, was tested in 598 people with Alzheimer's. Following the 12 month blinded phase of the study, TauRx announced that participants of the study have moved to an additional one-year open label phase.

According to TauRx's announcement, Professor Claude Wischik, Executive Chairman and Co-Founder of TauRx, commented: "The output indicates that participants receiving HMTM decline at a rate substantially less than is typical in Alzheimer's based on published research. This was seen for both cognitive and functional endpoints across a broad range of severity from mild cognitive impairment to moderate Alzheimer's. Importantly, the safety profile is favourable and consistent with previous studies".

TauRx informed that their data analysis is ongoing and will be reported at a later date. TauRx will be providing an update on their progress at the 35th Global Conference of Alzheimer's Disease to be held on 9 June 2022. TauRx has also stated that they will pursue regulatory submission and coverage for HMTM.

About GENTING:

Genting Berhad is principally an investment holding and management company. While the Company was incorporated in 1968 and listed in 1971, the Genting Group was founded in 1965 when its Founder, the late Tan Sri Lim Goh Tong started the journey to realise his vision of building a mountaintop resort in Malaysia. Today, the Genting Group comprises Genting Berhad and its listed companies; Genting Malaysia Berhad, Genting Plantations Berhad and Genting Singapore Limited, as well as its wholly owned unlisted subsidiaries Genting Energy Limited and Resorts World Las Vegas LLC.



GENTING

BERHAD

Registration No. 196801000315 (7916-A)

PRESS RELEASE

For Immediate Release

Led by Tan Sri Lim Kok Thay, the Group is involved in leisure and hospitality, oil palm plantations, power generation, oil and gas, property development, life sciences and biotechnology activities, with operations spanning across the globe, including in Malaysia (the Group's country of origin), Singapore, Indonesia, India, China, the United States of America, Bahamas, the United Kingdom and Egypt. In the core leisure and hospitality business, the Genting Group markets and offers a suite of products under a number of premier brands including **Genting, Resorts World, Genting Grand, Genting Club, Crockfords and Maxims**. The Genting Group has tie ups with established names such as Universal Studios, Premium Outlets, Zouk, Hard Rock Hotel, Hilton, Hyatt and other renowned international brand partners.

For more information, visit www.genting.com.

~ END OF RELEASE ~